DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin

Biochemical Pharmacology

Volumn 65, Issue 2, 2003, Pages 275-282

  Crul, Mirjam ^a   Van Waardenburg, Robert C A M ^a,b   Bocxe, Suzanne ^a   Van Eijndhoven, Maria A J ^a   Pluim, Dick ^a   Beijnen, Jos H ^a,c   Schellens, Jan H M ^a,c  

^a Netherlands C Inst/A van L Hosp   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cisplatin; DNA repair; Gemcitabine; Interaction

Indexed keywords

CISPLATIN; GEMCITABINE; PLATINUM;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CELL LINE; CHO CELL; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CHO CELLS; CISPLATIN; CRICETINAE; DEOXYCYTIDINE; DNA ADDUCTS; DNA REPAIR; DRUG SYNERGISM;

EID: 0037437791     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01508-3     Document Type: Article

References (42)

1. Crino L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., Salvati F., Cruciani G., Dogliotti L., Pucci F., Paccagnella A., Adamo V., Altavilla G., Incoronato P., Trippetti M., Mosconi A.M., Santucci A., Sorbolini S., Oliva C., Tonato M. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 15:1997;297-303.
2. Abratt R.P., Bezwoda W.R., Goedhals L., Hacking D.J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J. Clin. Oncol. 15:1997;744-749.
3. Hitt R., Castellano D., Hidalgo M., Garcia-Carbonero R., Pena M., Brandariz A., Millan J.M., Alvarez Vincent J.J., Cortes-Funes H. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann. Oncol. 9:1998;1347-1349.
4. Kaufman D., Raghavan D., Carducci M., Levine E.G., Murphy B., Aisner J., Kuzel T., Nicol S., Oh W., Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18:2000;1921-1927.
5. van der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 17:2000;3068-3077.
6. Burnett A.F., Roman L.D., Garcia A.A., Muderspach L.I., Brader K.R., Morrow C.P. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix. Gynecol. Oncol. 76:2000;63-66.
7. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., Lohman P.H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 24:1985;707-713.
8. Jones J.C., Zhen W.P., Reed E., Parker R.J., Sancar A., Bohr V.A. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem. 266:1991;7101-7107.
9. Sancar A. Mechanisms of DNA excision repair. Science. 266:1994;1954-1956.
10. Liu N., Lamerdin J.E., Tebbs R.S., Schild D., Tucker J.D., Shen M.R., Brookman K.W., Siciliano M.J., Walter C.A., Fan W., Narayana L.S., Zhou Z.Q., Adamson A.W., Sorensen K.J., Chen D.J., Jones N.J., Thompson L.H. XRCC2 and XRCC3 new human Rad51-family members promote chromosome stability and protect against DNA cross-links and other damages. Mol. Cell. 1:1998;783-793.
11. McHugh P.J., Sones W.R., Hartley J.A. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol. Cell Biol. 20:2000;3425-3433.
12. Thomson L.J., Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res. 477:2001;131-135.
13. McHugh P.J., Spanswick V.J., Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Onc. 2:2001;483-490.
14. Grossmann K.F., Ward A.M., Matkovic M.E., Folias A.E., Moses R.E. S. cerevisiae has three pathways for DNA interstrand crosslink repair. Mutat. Res. 487:2001;73-83.
15. Crul M., Schellens J.H.M., Beijnen J.H., Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat. Rev. 23:1997;341-366.
16. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
17. Gandhi V.M., Legha J., Chen F., Hertel L.W., Plunkett W. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 56:1996;4453-4459.
18. Achanta G., Pelicano H., Feng L., Plunkett W., Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res. 61:2001;8723-8729.
19. Ruiz van Haperen V.W.T., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem. Pharmacol. 46:1993;762-766.
20. Baker C.H., Banzon J., Bollinger J.M., Stubbe J., Samano V., Robins M.J., Lippert B., Jarvi E., Resvick R. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine: potent mechanism-based inhibitors of ribonucleotide reductase. J. Med. Chem. 34:1991;1879-1884.
21. van der Wilt C.L., Kroep J.R., Bergman A.M., Loves W.J., Alvarez E., Talianidis I., Eriksson S., van Groeningen C.J., Pinedo H.M., Peters G.J. The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv. Exp. Med. Biol. 486:2000;287-290.
22. Sun D., Urrabz R., Kelly S., Nguyen M., Weitman S. Enhancement of DNA ligase I level by gemcitabine in human cancer cells. Clin. Cancer Res. 8:2002;1189-1195.
23. Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:1996;521-530.
24. van Moorsel C.J.A., Pinedo H.M., Veerman G., Bergman A.M., Kuiper C.M., Vermorken J.B., van der Vijgh W.J., Peters G.J. Mechanism of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer. 80:1999;981-990.
25. Theodossiou C., Cook J.A., Fisher J., Teague D., Liebmann J.E., Russo A., Mitchell J.B. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int. J. Oncol. 12:1998;825-832.
26. Voigt W., Bulankin A., Muller T., Schoeber C., Grothey A., Hoang-Vu C., Schmoll H.J. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cells. Clin. Cancer Res. 6:2000;2087-2093.
27. van Moorsel C.J.A., Pinedo H.M., Smid K., Comijn E.M., Voorn D.A., Veerman G., Lakerveld B., van der Vijgh W.J., Giaccone G., Postmus P.E., Peters G.J. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur. J. Cancer. 36:2000;2420-2429.
28. Crul M, Schoemaker NE, Pluim D, Maliepaard M, Schot M, Sparidans RW, Baas P, Beijnen JH, van Zandwijk N, Schellens JHM. Phase I/II clinical and pharmacokinetic study of dose-intensive cisplatin and gemcitabine in patients with advanced non small cell lung cancer. Br J Clin Pharmacol, in press.
29. van Waardenburg R.C.A.M., de Jong L.A., van Delft F., Bohlander M., de Jong E.A., Verhage R., Brouwer J., Schellens J.H.M. The homologous recombination pathway is essential for the synergistic cytotoxicity between cisplatin and topoisomerase I inhibitors in lower and higher eukaryotes. Proc. AACR. 42:2001;3852. [Abstract].
30. Ma J., Maliepaard M., Nooter K., Boersma A.W., Verweij J., Stoter G., Schellens J.H.M. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother. Pharmacol. 41:1998;307-316.
31. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:1981;207-216.
32. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 86:1994;1517-1524.
33. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
34. Van Warmerdam L.J.C., van Tellingen O., Maes R.A.A., Beijnen J.H. Validated method for the determination of carboplatin in biological fluids by Zeeman Atomic Absorption Spectrometry. Fresenius' J. Anal. Chem. 351:1995;1820-1824.
35. 32P -Postlabeling assay for the quantification of the major platinum-DNA adducts Anal. Biochem. 275:1999;30-38.
36. Hoeijmakers J.H.J. Genome maintenance mechanisms for preventing cancer. Nature. 411:2001;366-374.
37. Li L., Peterson C.A., Lu X., Wei P., Legerski R.J. Interstrand cross-links induce DNA synthesis in damaged and undamaged plasmids in mammalian cell extracts. Mol. Cell Biol. 19:1999;5619-5630.
38. Kuraoka I., Kobertz W.R., Ariza R.R., Biggerstaff M., Essigmann J.M., Wood R.D. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J. Biol. Chem. 275:2000;26632-26636.
39. Lord R.V.M., Brabender J., Gandara D., Alberola V., Camps C., Domine M., Cardenal F., Sanchez J.M., Gumerlock P.H., Taron M., Sanchez J.J., Danenberg K.D., Danenberg P.V., Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8:2002;2286-2291.
40. Yang L.Y., Li L., Jiang H., Shen Y., Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin. Cancer Res. 6:2000;773-781.
41. Li L., Keating M.J., Plunkett W., Yang L.Y. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol. Pharmacol. 52:1997;798-806.
42. Swinnen L.J., Barnes D.M., Fisher S.G., Albain K.S., Fisher R.I., Erickson L.C. 1-Beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res. 49:1989;1383-1389.